RADNOR, PA — Pennsylvania-based biopharmaceutical company NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced a significant development in its ongoing clinical trial for a novel treatment for bipolar depression. The company has completed enrollment for its phase 2b/3 trial of NRX-101, a drug being tested for its efficacy against suicidal treatment-resistant bipolar depression.
The news was shared by Lotus Pharmaceutical Co. Ltd, NRx’s Asia Pacific strategic partner, during its financial filing on February 7. Lotus is part of NRx’s global partnership with Alvogen, Inc., and plays a crucial role in the Asia Pacific region.
Lotus reported that the readout from the NRX-101 trial is expected to be available in the second quarter of this year. The completion of enrollment marks an important milestone in the development of this potential new treatment.
Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals, expressed gratitude towards Lotus for its resources and commitment to advancing NRX-101. He highlighted the significant public health crisis posed by suicidal depression in Pacific rim countries, as reported by the World Health Organization, mirroring the situation in the US.
Willard recently held productive meetings at the JP Morgan conference in San Francisco. He emphasized the shared commitment between NRx and its partners to bring lifesaving treatment to patients who have been excluded from the clinical trials of all known antidepressants and whose only approved treatment today is electroshock therapy.
NRx anticipates further updates regarding its global partnerships in the near future. The successful completion of enrollment for the phase 2b/3 trial of NRX-101 is a promising step towards addressing the unmet need for effective treatments for suicidal treatment-resistant bipolar depression.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.